Jackson Square Capital’s NeoGenomics NEO Stock Holding History

Jackson Square Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,175	Closed	-$43K	–	269
2020 Q3	$43K	Sell	1,175 -485	-29%	-$18K	0.02%	181
2020 Q2	$51K	Sell	1,660 -293	-15%	-$8.12K	0.03%	158
2020 Q1	$54K	Sell	1,953 -247	-11%	-$7.4K	0.04%	119
2019 Q4	$64K	Buy	+2,200	New	+$52.4K	0.04%	144

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

KFO

Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jackson Square Capital's NEO Position: Q4 2020 in Review

Jackson Square Capital sold out of NeoGenomics (NEO) in Q4 2020, closing a stake of 1,175 shares — an estimated $43K sold.

Jackson Square Capital first reported a position in NEO in Q4 2019 and held it in 4 quarters. The position peaked at $64K in Q4 2019. 340 funds tracked by Wall St. Rank hold NEO as of Q4 2020.

Jackson Square Capital reported no remaining NeoGenomics position as of Q4 2020 after selling out during the quarter.
Jackson Square Capital sold 1,175 NeoGenomics shares in Q4 2020, an estimated $43K.
Jackson Square Capital first reported a position in NeoGenomics in Q4 2019 and held it in 4 quarters.
Jackson Square Capital's NeoGenomics position peaked at $64K in Q4 2019.
340 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2020.

Based on Jackson Square Capital's 13F filing for Q4 2020, filed 5 Mar 2021.